亿帆医药(002019.SZ)：F-652国内新增适应症移植物抗宿主病获临床试验批准

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its subsidiaries, Yiyisheng Biopharmaceutical Development (Shanghai) Co., Ltd. and Yiyisheng Biopharmaceutical (Beijing) Co., Ltd., have received approval from the National Medical Products Administration for a clinical trial of their investigational product, F-652, aimed at treating graft-versus-host disease (GVHD) in a Phase II clinical trial [1] Group 1 - The company has received the Clinical Trial Approval Notice for F-652 from the National Medical Products Administration [1] - The product F-652 is a recombinant human interleukin 22-Fc fusion protein [1] - The clinical trial will focus on treating graft-versus-host disease (GVHD) [1]